Darryl Sampey

Biography

Mr. Darryl Sampey is the Chief Science Officer and Co-Founder at BioFactura, Inc. Mr. Sampey co-founded BioFactura in 2001 and manages all scientific endeavors of the Company including contract research and development, platform technology programs, and biopharmaceutical product development. Before BioFactura, he led both process development and manufacturing teams at Human Genome Sciences, Inc. (HGS). Mr. Sampey joined the protein development department of HGS in 1998, and honed his skills developing new biologics processes and control strategies. During his tenure with HGS, Mr. Sampey played key roles in the start-up, commissioning, and validation of the company's first cGMP manufacturing facility and associated development laboratories. Additionally, he performed lead roles in the development, transfer, and evaluation of novel fermentation processes for cGMP clinical manufacturing. Prior to his work at HGS, Mr. Sampey gained industrial experience in the commercial research laboratory designing and optimizing fermentation and product recovery processes for novel vaccines at North American Vaccine, Inc. His work in vaccine research has since progressed to internationally-approved vaccines for whooping cough in infants and meningitis in adults. Darryl Sampey began his career in biotechnology at the University of Maryland. During his undergraduate years, Mr. Sampey pursued independent research in novel protein analysis technique under the advisement of Dr. William Bentley. Mr. Sampey graduated first in his class and was awarded a Bachelor of Science in Chemical Engineering, Magna Cum Laude. He is currently pursuing his Ph.D. in Bioengineering at the University of Maryland.  

Research Interest

 Biotechnology, Human Genome Project.